These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma. Khoury R; Chahine C; Ibrahim R; Khalife N; Saleh M; Saleh K Future Oncol; 2023 Jun; 19(17):1161-1163. PubMed ID: 37293779 [No Abstract] [Full Text] [Related]
12. Role of molecular genetics in the clinical management of cholangiocarcinoma. Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744 [TBL] [Abstract][Full Text] [Related]
13. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology. Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450 [TBL] [Abstract][Full Text] [Related]
14. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. King G; Javle M Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915 [TBL] [Abstract][Full Text] [Related]